Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026. AN2 WILL HAVE THREE PHASE 2 PROGRAMS UNDERWAY BY THE END OF THIS YEAR, ALL OF WHICH HAVE THE POTENTIAL TO ADDRESS MAJOR UNMET NEEDS. OUR NEAR-TERM FOCUS IS ADVANCING START-UP ACTIVI.

AN2 THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX) A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED POSITIVE RESULTS FROM TWO STUDIES EVALUATING THE COMPANY'S ORAL CPSF3 INHIBITOR, AN2-502998, FOR THE TREATMENT OF CHRONIC CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY INFECTION WITH THE PARASITE T. CRUZI. KEY FINDINGS FROM THE TWO STUDIES: IN NHPS WITH NATURALLY ACQUIRE.

AN2 THERAPEUTICS REPORTS POSITIVE ENABLING DATA SUPPORTING ADVANCEMENT OF ORAL AN2-502998 TO PHASE 2 STUDY FOR CHRONIC CHAGAS DISEASE

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY ADVANCING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND CEO WILL PRESENT AT THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON JUNE 4, 2026 AT 12:50 PM ET, AND MEMBERS OF MANAGEMENT WILL BE AVAILABLE FOR 1X1 MEETINGS. A WEBCAST CAN BE ACCESSED ON THE INVESTORS SECTION OF THE AN2 THERAPEUTICS WE.

AN2 THERAPEUTICS TO PRESENT AT 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. THIS WAS AN IMPORTANT QUARTER FOR AN2 AS WE ANNOUNCED AN EXCITING NEW PROGRAM IN POLYCYTHEMIA VERA THAT IS PLANNED TO ENTER PHASE 2 DEVELOPMENT IN THE THIRD QUARTER OF 2026. THIS PR.

AN2 THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY ADVANCING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND CEO WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM ON MAY 19, 2026 AT 4:00 PM ET, AND MEMBERS OF MANAGEMENT WILL BE AVAILABLE FOR 1X1 MEETINGS. A WEBCAST CAN BE ACCESSED ON THE INVESTORS SECTION OF T.

AN2 THERAPEUTICS TO PARTICIPATE IN 2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THE INITIATION OF A PHASE 2 INVESTIGATOR-INITIATED CLINICAL TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF EPETRABOROLE, AN ORALLY ADMINISTERED INHIBITOR OF LEUCYL-TRNA SYNTHETASE (LEURS), FOR THE TREATMENT OF PULMONARY DISEASE CAUSED BY MYCOBACTERIUM ABSCESSU.

AN2 THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 INVESTIGATOR-INITIATED CLINICAL TRIAL OF EPETRABOROLE FOR MYCOBACTERIUM ABSCESSUS COMPLEX LUNG DISEASE

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2025. OUR RECENT DECISION TO ADVANCE ORAL EPETRABOROLE INTO A PHASE 2 STUDY FOR POLYCYTHEMIA VERA HIGHLIGHTS THE GROWING OPPORTUNITY ACROSS AN2'S BORON CHEMISTRY PIPELINE AND.

AN2 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS AND SCIENTIFIC HIGHLIGHTS

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR A PRIVATE PLACEMENT THAT IS EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $40 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER EXPENSES. THE PRIVATE PLACEMENT INCLUDES PARTICIPATION FROM COASTLANDS C.

AN2 THERAPEUTICS ANNOUNCES $40 MILLION PRIVATE PLACEMENT FINANCING

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED ITS PLANS TO EXPAND THE DEVELOPMENT OF ORAL EPETRABOROLE INTO A PHASE 2 PROOF-OF-CONCEPT CLINICAL STUDY IN ADULTS WITH PHLEBOTOMY-DEPENDENT POLYCYTHEMIA VERA (PV). PV IS A BLOOD CANCER CHARACTERIZED BY OVERPRODUCTION OF RED BLOOD CELLS IN THE BONE MARROW. THIS OVERPRODUCTION.

AN2 THERAPEUTICS ANNOUNCES PLANS TO ADVANCE ORAL EPETRABOROLE INTO PHASE 2 STUDY FOR POLYCYTHEMIA VERA (PV)

MENLO PARK, CALIF.--(BUSINESS WIRE)--AN2 THERAPEUTICS, INC. (NASDAQ: ANTX), A BIOPHARMACEUTICAL COMPANY ADVANCING NOVEL SMALL MOLECULE THERAPEUTICS DERIVED FROM ITS BORON CHEMISTRY PLATFORM, TODAY ANNOUNCED THAT ERIC EASOM, CO-FOUNDER, CHAIRMAN, PRESIDENT AND CEO WILL PARTICIPATE IN A FIRESIDE CHAT AT THE LEERINK GLOBAL HEALTHCARE CONFERENCE ON MARCH 10, 2026 AT 3:40 PM ET. A WEBCAST CAN BE ACCESSED ON THE INVESTORS SECTION OF THE AN2 THERAPEUTICS WEBSITE AT WWW.AN2THERAPEUTICS.COM. AN ARCHIVED.

AN2 Therapeutics, Inc.

ANTX

Price

Financial Reports

No items found.

Press Releases

AN2 Therapeutics, Inc.

ANTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ANTX